Profiling of copy number alterations using low-coverage whole-genome sequencing informs differential diagnosis and prognosis in primary cutaneous follicle center lymphoma.


Journal

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605

Informations de publication

Date de publication:
07 Mar 2024
Historique:
received: 22 09 2023
revised: 21 02 2024
accepted: 01 03 2024
medline: 10 3 2024
pubmed: 10 3 2024
entrez: 9 3 2024
Statut: aheadofprint

Résumé

Primary cutaneous follicle center lymphoma (PCFCL) has an excellent prognosis using local treatment, while nodal follicular lymphoma (nFL) occasionally presenting with cutaneous spread, often requires systemic therapy. Distinction of the two diseases based on histopathology alone might be challenging. Copy number alterations (CNAs) have scarcely been explored on a genome-wide scale in PCFCL, yet they might serve as potential biomarkers during differential diagnosis and risk stratification. Low-coverage whole genome sequencing (lcWGS) is a robust, high-throughput method for genome-wide copy number profiling. In this study, we analyzed 28 PCFCL samples from 20 patients and compared the copy number profiles to a cohort of diagnostic samples of 64 nFL patients. Although the copy number profile of PCFCL was similar to that of nFL, PCFCL lacked amplifications of 18q, with the frequency peaking at 18q21.33 in nFL cases involving the BCL2 locus (PCFCL: 5.0% vs. nFL: 31.3%, p=0.018, Fisher's exact test). Development of distant cutaneous spread was significantly associated with higher genomic instability including the proportion of genome altered (0.02 vs. 0.13, p=0.033) and number of CNAs (2 vs. 9 p=0.017), as well as the enrichment of 2p22.2-p15 amplification involving REL and XPO1 (6.3% vs. 60.0%, p=0.005), 3q23-q24 amplification (0.0% vs. 50.0%, p=0.004), 6q16.1-q23.3 deletion (6.3% vs. 50.0%, p=0.018) and 9p21.3 deletion covering CDKN2A and CDKN2B loci (0.0% vs. 40.0%, p=0.014, all Fisher's exact test) in PCFCL. Analysis of sequential tumor samples in two cases harboring an unfavorable clinical course pointed to the acquisition of 2p amplification in the earliest common progenitor underlining its pivotal role in malignant transformation. By performing genome-wide copy number profiling on the largest patient cohort to date, we identified distinctive CNA alterations conceivably facilitating the differential diagnosis of PCFCL and secondary cutaneous involvement of nFL, and potentially aiding the risk stratification of patients with PCFCL in the future.

Identifiants

pubmed: 38460675
pii: S0893-3952(24)00045-0
doi: 10.1016/j.modpat.2024.100465
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100465

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Bence Bátai (B)

HCEMM-SU Molecular Oncohematology Research Group, Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary; Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary.

Laura Kiss (L)

HCEMM-SU Molecular Oncohematology Research Group, Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.

Luca Varga (L)

HCEMM-SU Molecular Oncohematology Research Group, Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.

Ákos Nagy (Á)

HCEMM-SU Molecular Oncohematology Research Group, Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary; Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary.

Jacob Househam (J)

Genomics and Evolutionary Dynamics Team, Centre for Evolution and Cancer, The Institute for Cancer Research, London, United Kingdom.

Ann-Marie Baker (AM)

Genomics and Evolutionary Dynamics Team, Centre for Evolution and Cancer, The Institute for Cancer Research, London, United Kingdom.

Tamás László (T)

HCEMM-SU Molecular Oncohematology Research Group, Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.

Anna Udvari (A)

HCEMM-SU Molecular Oncohematology Research Group, Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.

Róbert Horváth (R)

HCEMM-SU Molecular Oncohematology Research Group, Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.

Tibor Nagy (T)

HCEMM-SU Molecular Oncohematology Research Group, Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary; Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Judit Csomor (J)

Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.

József Szakonyi (J)

Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary.

Tamás Schneider (T)

Department of Hematology and Lymphoma, National Institute of Oncology, Budapest, Hungary.

Trevor A Graham (TA)

Genomics and Evolutionary Dynamics Team, Centre for Evolution and Cancer, The Institute for Cancer Research, London, United Kingdom.

Donát Alpár (D)

HCEMM-SU Molecular Oncohematology Research Group, Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.

Jude Fitzgibbon (J)

Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.

Ágota Szepesi (Á)

Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary. Electronic address: szepesi.agota@semmelweis.hu.

Csaba Bödör (C)

HCEMM-SU Molecular Oncohematology Research Group, Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary. Electronic address: bodor.csaba1@semmelweis.hu.

Classifications MeSH